Hepatocellular carcinoma
Conditions
Interventions
Product name: IA-call Product name: Hepasphere Protocol treatment procedure: Perform DEB-TACE using Hydrocol-impregnated Hepaspire from hepatic arterial segment branches according to the area to
Sponsors
okayama university hospital
Okayama saiseikai general hospital, Okayama city general medical center, Japanese red cross Okayama hospital, Kagawa prefectural central hospital, Kurashiki central hospital, Tsuyama chuo hospital, Hiroshima city Hiroshima citizens hospital, Mitoyo general hospital, Himeji central hospital, Fukuyama city hospital, National hospital organization Fukuyama medical center, Sumitomo Bessshi hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: HCC tumor number 3 < tumor size < 30mm Child-Pugh A or B BCLC stage A or B Age 20-90 ECOG performance status 0-1 4 week later after previous therapy TACE therapy within 4 times Laboratory data is in normal range get concent in writing expect survival for over 8 weeks
Exclusion criteria
Exclusion criteria: not HCC previously treated by hepatic arterrial infusion therapy invesion of artery, vein or biliary duct extrahepatic lesion HCC rupture unsuitable for TACE HCC dominated by localized vessels unsuitable for CDDP To have other cancers To have serious complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate(treated after four-twelve weeks) | — |
Countries
Japan
Contacts
Public ContactAtsushi Oyama
okayama university hospital Gastroenterology and Hepatology
Outcome results
None listed